# Effect of Atorvastatin on Carotid Intima Media Thickness

Study · id `cardio:ct-nct04306627` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT04306627](<https://clinicaltrials.gov/study/NCT04306627>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT04306627

Browse, organ or system: Blood vessels; Metabolism  
Browse, condition area: Risk and prevention; High blood pressure; Diabetes and metabolic disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 200 participants.

## Technical summary

Registry record NCT04306627. Randomized; no masking; primary purpose treatment. Start 2020-04-15 (anticipated); primary completion 2020-10-16 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 200 participants (planned count; ClinicalTrials.gov record NCT04306627, source copy `cardio:ctgov-nct04306627-2020-03-13`, retrieved 2026-10-26)
- Planned start: 2020-04-15 (anticipated) (ClinicalTrials.gov record NCT04306627, source copy `cardio:ctgov-nct04306627-2020-03-13`, retrieved 2026-10-26)
- Primary completion: 2020-10-16 (anticipated) (ClinicalTrials.gov record NCT04306627, source copy `cardio:ctgov-nct04306627-2020-03-13`, retrieved 2026-10-26)
- Completion: 2021-02-28 (anticipated) (ClinicalTrials.gov record NCT04306627, source copy `cardio:ctgov-nct04306627-2020-03-13`, retrieved 2026-10-26)
- Countries: Not reported
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct04306627-2020-03-13`, retrieved 2026-10-26)

## The registry's words

- Brief title: Effect of Atorvastatin on Carotid Intima Media Thickness
- Condition: Essential Hypertension
- Condition: Hypercholesterolemia
- Intervention (Drug): Perindopril/Amlodipine and Perindopril/Amlodipine/Atorvastatin treatment
- Lead sponsor: Yerevan State Medical University
- Lead sponsor class: OTHER
- Collaborator: Servier
- Collaborator class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Dyslipidemia (`cardio:dyslipidemia`)
- Registry condition terms include this condition: High cholesterol (hypercholesterolemia) (`cardio:hypercholesterolemia`)
- Registry condition terms include this condition: Hypertension (high blood pressure) (`core:hypertension`)

## Provenance

Content hash: 9abe589537dacd42dae6e505004acff48ff5264bd705e7fc800fc4296edcffa2
Last substantive edit: 2026-10-31
Evidence last checked: Not recorded
